Results 1 to 10 of about 16,593 (260)
Nanobody based dual specific CARs [PDF]
International Journal of Molecular Sciences, 2018 Recent clinical trials have shown that adoptive chimeric antigen receptor (CAR) T cell therapy is a very potent and possibly curative option in the treatment of B cell leukemias and lymphomas.
Abken, Hinrich +8 more
core +6 more sources
Identification and in vivo characterization of a brain-penetrating nanobody [PDF]
Fluids and Barriers of the CNS, 2020 Background Preclinical models to determine blood to brain transport ability of therapeutics are often ambiguous. In this study a method is developed that relies on CNS target-engagement and is able to rank brain-penetrating capacities. This method led to
Y Wouters +3 more
doaj +2 more sources
Development of camelid monoclonal nanobody against SLC39A6 zinc transporter protein [PDF]
Iranian Journal of Basic Medical Sciences, 2021 Objective(s): SLC39A6 (solute carrier family 39) or LIV-1, is a zinc-transporter protein associated with estrogen-positive breast cancer and its metastatic spread.
Hajarsadat Ghaderi +4 more
doaj +1 more source
Structure of Nanobody Nb23 [PDF]
Molecules, 2021 Background: Nanobodies, or VHHs, are derived from heavy chain-only antibodies (hcAbs) found in camelids. They overcome some of the inherent limitations of monoclonal antibodies (mAbs) and derivatives thereof, due to their smaller molecular size and higher stability, and thus present an alternative to mAbs for therapeutic use.
Percipalle M. +4 more
openaire +5 more sources
Seminars in Immunology, 2021 For treatment and diagnosis of cancer, antibodies have proven their value and now serve as a first line of therapy for certain cancers. A unique class of antibody fragments called nanobodies, derived from camelid heavy chain-only antibodies, are gaining increasing acceptance as diagnostic tools and are considered also as building blocks for chimeric ...
Elisha R, Verhaar +2 more
openaire +3 more sources
Signal Transduction and Targeted Therapy, 2021 Chimeric antigen receptor-based T-cell immunotherapy is a promising strategy for treatment of hematological malignant tumors; however, its efficacy towards solid cancer remains challenging.
Fengzhen Mo +17 more
doaj +1 more source
Screening, Expression, and Identification of Nanobody against SARS-CoV-2 Spike Protein
Cells, 2022 Coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an infectious disease that has become a serious burden on global public health.
Qianling Su +11 more
doaj +1 more source
Antibodies, 2020 Since their first description in 1993 [...]
Patrick Chames, Ulrich Rothbauer
openaire +3 more sources
Journal of Hematology & Oncology, 2023 Background T cell engagers (TCEs) have been established as an emerging modality for hematologic malignancies, but solid tumors remain refractory. However, the upregulation of programmed cell death 1 (PD-1) is correlated with T cell dysfunction that ...
Ziqiang Ding +12 more
doaj +1 more source
Recent advances of nanobody applications in diagnosis and detection
MedComm – Biomaterials and Applications, 2023 Nanobodies (Nbs) are the variable domain of heavy‐chain antibodies derived from the blood of camelids or sharks. Nanobodies are the smallest antibody fragment with intact antigen‐binding ability.
Qianling Su +5 more
doaj +1 more source